Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment, as well as the progression of a second drug candidate ...

The company has several newer products with fast-growing sales, notably including migraine therapy Nurtec ODT and cancer drugs Adcetris and Padcev. Pfizer's pipeline features 32 programs in late ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

The portfolio of Royalty Pharma Plc (NASDAQ:RPRX) comprises royalties in more than 35 marketed drugs, such as Pfizer’s Nurtec ODT, Novartis’ Promacta, AbbVie and Johnson & Johnson’s ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

Akili Scope achieved breakthrough status for ADHD treatment from the FDA in May 2023. In March 2023, Biohaven’s Nurtec ODT gained FDA approval for preventing migraines, becoming the sole oral ...